Breast Cancer Metastasis and Drug Resistance

<p>1.&nbsp;Breast Cancer Statistics: Recent trends</p><p>2. Epidemiology of Breast Cancer in Women<br></p><p>3.&nbsp;Health and Racial Disparity in Breast Cancer<br></p><p>4.Breast Cancer: Current perspectives on the disease status<br></p><p>5. Role of Autophagy in Breast Cancer Development and Progression: Opposite Sides of the Same Coin<br></p><p>6. Breast Cancer Heterogeneity in Primary and Metastatic Disease<br></p><p>7. Bone Metastasis of Breast Cancer&nbsp;<br></p><p>8. Therapeutic Options for Metastatic Breast Cancer<br></p><p>9.Chemotherapy and inflammatory cytokine signalling in cancer cells and the tumour microenvironment<br></p><p>10. Current Updates on Trastuzumab Resistance in HER2 overexpressing Breast Cancers<br></p><p>11.Non-coding RNAs as mediators of tamoxifen resistance in breast cancers<br></p><p>12.&nbsp;TRAIL Mediated Signaling in Breast Cancer: Awakening Guardian Angel to Induce Apoptosis and Overcome Drug Resistance<br></p><p>13.&nbsp;Current state of platinum complexes for the treatment of advanced and drug-resistant breast cancers<br></p><p>14.Targeting of JAK-STAT Signaling in Breast Cancer: Therapeutic Strategies to Overcome Drug Resistance<br></p><p>15. Role of mTORC1 and mTORC2 in Breast Cancer: Therapeutic Targeting of mTOR and its Partners to Overcome Metastasis and Drug Resistance<br></p><p>16. Epigenetics of Breast Cancer: Clinical Status of Epi-Drugs and Phytochemicals<br></p><p>17. Targeting CSC in a most aggressive subtype of breast cancer TNBC<br></p><p>18.&nbsp;Cross-roads to drug resistance and metastasis in breast cancer: miRNAs regulatory function and biomarker capability<br></p><p>19. NEDD4 Family of E3 Ubiquitin Ligases in Breast Cancer: Spotlight on SMURFs, WWPs and NEDD4<br></p><p>20. Emerging Novel Therapeutics in Triple-Negative Breast Cancer<br></p><p>21.Breast Cancer: Proteolysis and Migration<br></p>22.Current and emerging 3D models to study breast cancer